Compare CTRA & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRA | GMAB |
|---|---|---|
| Founded | 1989 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.6B | 20.4B |
| IPO Year | 1990 | N/A |
| Metric | CTRA | GMAB |
|---|---|---|
| Price | $25.49 | $33.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 6 |
| Target Price | $32.81 | ★ $40.40 |
| AVG Volume (30 Days) | ★ 6.9M | 1.6M |
| Earning Date | 02-23-2026 | 02-11-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | 31.20 | ★ 132.41 |
| EPS | 2.17 | ★ 25.10 |
| Revenue | ★ $6,666,000,000.00 | $3,845,670,022.00 |
| Revenue This Year | $47.54 | $24.85 |
| Revenue Next Year | $5.27 | $16.51 |
| P/E Ratio | $11.67 | ★ $1.35 |
| Revenue Growth | 25.92 | ★ 29.57 |
| 52 Week Low | $22.33 | $17.24 |
| 52 Week High | $29.95 | $33.99 |
| Indicator | CTRA | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.42 | 60.57 |
| Support Level | $24.74 | $30.35 |
| Resistance Level | $26.70 | $33.96 |
| Average True Range (ATR) | 0.58 | 0.69 |
| MACD | -0.11 | 0.07 |
| Stochastic Oscillator | 37.50 | 91.62 |
Coterra Energy Inc is an independent oil and gas company engaged in the development, exploration, and production of oil, natural gas, and natural gas liquids (NGLs). Its operations are mainly concentrated in areas with hydrocarbon resources, which are conducive to multi-well, repeatable development programs, and include the Permian Basin located in Texas and New Mexico, the Marcellus Shale in northeast Pennsylvania, and the Anadarko Basin located in the mid-continent region in Oklahoma. The company operates in one segment, oil and natural gas development, exploration, and production, in the continental U.S.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.